– First evidence of treatment-related remyelination in the human central nervous system – – Ongoing SYNERGY trial will further inform potential for anti-LINGO-1 in MS – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Today, Biogen (NASDAQ: BIIB) announced detailed results from the Phase 2 RENEW study of anti-LINGO-1 in acute optic neuritis (AON) – the first clinical study […]
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
The top pharmaceutical companies are trying to proactively tackle, through shifts in R&D strategy and other tactics, the healthcare demands of the future.
This yearly review analyzes recent developments, trends and outlooks in the areas of biotechnology, biosimilars, biopharmaceuticals, biologics, biomarkers and biobanks.
BALTIMORE, Apr. 15, 2015 /PRNewswire/ –Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has issued a new research update on PharmaCyte Biotech, Inc. (OTCQB – PMCB), a publicly traded, clinical stage biotechnology company focused on developing and preparing treatments for cancer and […]
(Reuters) – Having seen off a hostile $118 billion bid launched a year ago by U.S. rival Pfizer, Anglo-Swedish company AstraZeneca is on the move — quite literally. As of last month, a four-days-a-week service set up by the drugmaker with Sun Air is connecting staff in its new Cambridge science and operations hub with […]
Avanir Pharmaceuticals Announces Multiple Data Presentations Highlighting Its Central Nervous System (CNS) Therapeutics Franchise at the American Academy of Neurology (AAN) 2015 Annual Meeting
ALISO VIEJO, Calif., April 15, 2015 /PRNewswire/ — Avanir Pharmaceuticals, Inc. today announced that data highlighting its central nervous system (CNS) therapeutics franchise, including data from the Phase 2 study of AVP-923 for the treatment of agitation in Alzheimer’s disease, data from the Alzheimer’s cohort of PRISM II of NUEDEXTA® for the treatment of Pseudobulbar […]
Oncobiologics announces completion of clinical dosing for bevacizumab (Avastin biosimilar) candidate
CRANBURY, N.J., April 15, 2015 /PRNewswire/ — Oncobiologics, Inc., a biotherapeutics company focused on developing and commercializing biosimilars, today announced that clinical development for ONS-1045, an Avastin®/bevacizumab biosimilar candidate, is underway with dosing completed in its pivotal pharmacokinetic (PK) study. This study is currently being conducted at the Center for Human Drug Research (CHDR) in Leiden, […]
Traumatic events during childhood may increase kids’ risk of developing type 1 diabetes, a Swedish study suggests. The researchers questioned more than 10,000 families and found that children who experienced an extremely stressful life event – like divorce, illness or death in the family – were about three times more likely to develop type 1 […]
The Pfizer logo is seen at their world headquarters in New York April 28, 2014. Reuters/Andrew Kelly Pfizer Inc said on Wednesday the first formal late-stage trial of its approved treatment for advanced breast cancer, Ibrance, was stopped early after the medicine met its goal of delaying progression of the disease in previously treated patients. […]
COPENHAGEN, Denmark–(BUSINESS WIRE)–Today, ReSound introduced the first hearing aid app designed specifically for Apple Watch. Available immediately to Apple Watch wearers, the ReSound Smart™ app for Apple Watch offers a new, streamlined user experience, allowing users to take advantage of seamless, on-the-go control, right from their wrist. The ReSound Smart app for Apple Watch marks the latest of the company’s efforts to bring forward-looking solutions […]
Medical Marijuana Extract Curbs Seizure Frequency In Early Trial Of Epilepsy Patients Epilepsy Researchers Hope to Replicate Promising Cannabidiol Findings in Randomized Controlled Studies A new study led by epilepsy specialists at NYU Langone Medical Center shows that some children and adults with treatment-resistant epilepsy may benefit from a treatment regimen including cannabidiol, a compound […]
Reuters Health | Tue Apr 14, 2015 5:22pm EDT BY BEN GRUBER BERKELEY, CALIFORNIA – Bioengineers in California have developed a system that allows human heart cells to function outside the body, a development that could potentially prove a powerful tool for drug development as well as pave the way toward personalizing treatments for patients with heart conditions. […]